Gastroenterology

A related editorial noted the study authors’ numbers were higher than those of the Mayo Clinic.

About half of patients experienced adverse events, and two-thirds of those events were likely related to inflammatory bowel disease medications.

Researchers suggest bolstering beneficial gut species depleted in COVID-19 could mitigate severe disease.

It’s possible that C diff could be a marker for frailty in geriatric patients.

The negative effects of the pandemic may disrupt efforts to eradicate HBV as a public health threat by 2030.

Using piperacillin/tazobactam increases the risk for acute kidney injury, and this risk can be exacerbated by concurrent vancomycin.

New phase 3 data show the IL-23 inhibitor is associated with clinical remission and endoscopic response.

Anastomotic leak can increase morbidity, mortality, and length and cost of hospital stays.

There is not currently an FDA approved treatment for NASH.

Investigators compared the 2010 and 2017 IDSA and SHEA guidelines to identify which better predicted C diff patients’ severity and mortality.

The first approved generic product for injection glucagon is also indicated for diagnostic use, when appropriate.

Screening for hepatitis B virus has become the norm in patients about to undergo anti-tumor-necrosis factor α therapy, but new research finds the risk of reactivation of resolved infections is low.

The investigators called their findings the “opposite of what was expected.”

The study authors wrote that understanding this phenomena can lead to determining the best therapeutic strategy with DAAs for certain patients.

The investigators measured a 3.5-month period before and after a policy was implemented to preserve hospital resources.

The TARGET-NASH study seeks to shed light on treatment for NASH and NAFLD.

Experts offered their advice on 2 domains, topic identification and ranking of priorities, for pediatric research realms.

Hepatitis B coinfection with COVID-19 did not increase either disease’s severity or increase duration of hospitalization, according to a small study in China.

Harvey Alter, Michael Houghton, and Charles Rice were awarded with the 2020 Nobel Prize in Physiology and Medicine.

There was not a statistically significant difference in eGFR between kidney recipients of HCV positive and negative donors.

Despite the increasing push for using HCV-positive organs to expand the donor pool, hundreds of livers allografts from donors are still not being used in transplantation.

Approximately 30% of patients treated with upadacitinib achieved endoscopic mucosal improvement at week 8, compared to just 7% of the placebo group

This combination therapy may have a few advantages over standard corticosteroid regimens.